Sapitinib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameSapitinib
Drug Alias Name沙匹替尼Sapitinibum沙普替尼AZD-8931
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor tyrosine-protein kinase erbB-3 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesAstrazeneca Pharmaceutical Co LtdUniversity College London
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursNeoplasm MetastasisStomach Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A